Natera
Trade Natera 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).
NTRA Key Statistics
Stock Snapshot
With a market cap of 47.86B, Natera(NTRA) trades at $332.03. The stock has a price-to-earnings ratio of -242.61.
On 2026-08-22, Natera(NTRA) stock moved within a range of $320.41 to $332.98. With shares now at $332.03, the stock is trading +3.6% above its intraday low and -0.3% below the session's peak.
Trading activity shows a volume of 1.21M, compared to an average daily volume of 1.46M.
Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $333.56 and a low of $157.43.
Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $333.56 and a low of $157.43.
NTRA News
Natera Inc. ((NTRA)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful investing...
IBD 50 Stock Natera Zips Above Profit-Taking Zone On Its Blowout Quarter 8/07/2026 Natera stock surged Friday after reporting blowout volume for its cancer-det...
Key Points Billionaire investor Stanley Druckenmiller holds an $865 million position in Natera. Shares in the diagnostics company have surged over 37% year to...
Analyst ratings
88%
of 24 ratingsMore NTRA News
In recent days, Kupando Therapeutics announced a collaboration using Natera’s Latitude tissue-free MRD assay to monitor ctDNA dynamics in a Phase 1 trial of its...
Stephens raised the firm’s price target on Natera (NTRA) to $350 from $305 and keeps an Overweight rating on the shares. The firm is updating its model followin...
Natera (NTRA) is back in focus after agreeing to supply its Latitude molecular residual disease test for Kupando Therapeutics’ Phase 1 trial of lead immunothera...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.